Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 21;3(5):737-741.
doi: 10.1016/j.jaccao.2021.09.014. eCollection 2021 Dec.

How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk: A Therapeutic Tightrope

Vivek Narayan  1 , Ashley E Ross  2 , Ravi B Parikh  1 , Anju Nohria  3 , Alicia K Morgans  4
Affiliations
Review

How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk: A Therapeutic Tightrope

Vivek Narayan et al. JACC CardioOncol. .
No abstract available

Keywords: ADT, androgen deprivation therapy; ARSI, androgen receptor signaling agent; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factor; GnRH, gonadotropin-releasing hormone; RT, radiation therapy; cancer survivorship; hormonal therapy; mCSPC, metastatic castration-sensitive prostate cancer; prostate cancer; risk factor.

PubMed Disclaimer

Conflict of interest statement

Dr Narayan has received research support from Bristol-Myers Squibb, Merck, TMunity Therapeutics, Pfizer, and Janssen; and consulting fees from Janssen, Pfizer, Myovant, Amgen, Regeneron, and Merck. Dr Ross has received consulting/speaker fees from Astellas, Bayer, Blue Earth, GenomeDx Biosciences, Janssen, Myovant, and Tempus. Dr Parikh has received grant support from Humana, the National Institutes of Health, the Prostate Cancer Foundation, the National Palliative Care Research Center, the Conquer Cancer Foundation, and the Veterans Administration; received personal fees and equity from GNS Healthcare and Onc.AI; received personal fees from the Cancer Study Group and Nanology; and honorarium from Flatiron and Medscape; and served on the board (unpaid) of the Coalition to Transform Advanced Care. Dr Nohria has received research support from Amgen; and served as a consultant for AstraZeneca, Bantam Pharmaceuticals, Boehringer Ingelheim, and Takeda Oncology. Dr Morgans has received research support from Astellas, Seattle Genetics, Bayer, Sanofi, and Myovant; and consulting fees from Astellas, AstraZeneca, AAA, Bayer, Clovis, Janssen, Dendreon, Myovant, Merck, Exelixis, Novartis, Pfizer, Blue Earth, Myriad, Sanofi, and Lantheus.

Figures

None
Graphical abstract
Figure 1
Figure 1
Cardiometabolic Effects of Androgen Suppression Therapies in Prostate Cancer This figure describes the mechanisms of androgen suppression for commonly used prostate cancer therapies. Adapted with permission from Hahn VS, Zhang KW, Sun L, et al. Circ Res. 2021;128:1576-1593. Cardiometabolic toxicities of androgen suppression are displayed. FSH = follicle-stimulating hormone; GnRH = gonadotropin-releasing hormone; LH = luteinizing hormone.
Figure 2
Figure 2
Factors Influencing Cancer Control, Treatment-Related Toxicity, and Cardiovascular Outcomes This figure describes the competing risks for morbidity and mortality in prostate cancer patients receiving systemic androgen deprivation therapy, including cancer-related, treatment-related, and cardiovascular-related risks. A recommendation is suggested for monitoring and management of cardiovascular risk factors (CVRFs) and cardiovascular disease (CVD). ADT = androgen deprivation therapy; ARSI = androgen receptor signaling agent; BMI = body mass index; BP = blood pressure; GnRH = gonadotropin-releasing hormone; HbA1c = glycosylated hemoglobin.
See this image and copyright information in PMC

References

    1. Shore N.D., Saad F., Cookson M.S., et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382:2187–2196. - PubMed
    1. Hershman D.L., Unger J.M., Wright J.D., et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2:453–461. - PMC - PubMed
    1. O'Farrell S., Garmo H., Holmberg L., et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33:1243–1251. - PubMed
    1. Levine G.N., D'Amico A.V., Berger P., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association. Circulation. 2010;121:833–840. - PMC - PubMed
    1. Bill-Axelson A., Holmberg L., Garmo H., et al. Radical prostatectomy or watchful waiting in prostate cancer – 29-year follow-up. N Engl J Med. 2018;379:2319–2329. - PubMed